Evidence map›Paper›PMID 32583494›Full record

ArticleInternational journal of clinical practice2021

Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma.

Hikmet Akkiz, Brian I Carr, Harika G Bag, Ümit Karaoğullarından, Kendal Yalçın, Nazim Ekin, Ayşegül Özakyol, Engin Altıntaş, Hatice Y Balaban, Halis Şimşek and 7 more

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 1 country.

Hikmet AkkizÇukurova University, Adana, Turkey.
Brian I Carrİnönü University, Malatya, Turkey.ORCID https://orcid.org/0000-0002-6111-5077
Harika G Bagİnönü University, Malatya, Turkey.
Ümit KaraoğullarındanÇukurova University, Adana, Turkey.
Kendal YalçınDikle University, Diyarbakır, Turkey.
Nazim EkinDikle University, Diyarbakır, Turkey.
Ayşegül ÖzakyolEskişehir Osmangazi University, Eskişehir, Turkey.
Engin AltıntaşMersin University, Mersin, Turkey.
Hatice Y BalabanHacettepe University, Ankara, Turkey.ORCID https://orcid.org/0000-0002-0901-9192
Halis ŞimşekHacettepe University, Ankara, Turkey.
Ahmet UyanıkoğluHarran University, Şanlıurfa, Turkey.
Ayhan BalkanGaziantep University, Gazientep, Turkey.
Sedef KuranÇukurova University, Adana, Turkey.
Oğuz ÜsküdarÇukurova University, Adana, Turkey.
Yakup ÜlgerÇukurova University, Adana, Turkey.
Burak GüneyÇukurova University, Adana, Turkey.
Anil DelikÇukurova University, Adana, Turkey.
Cukurova University · TRDicle University · TRHacettepe University · TRInonu University · TREskişehir Osmangazi University · TRGaziantep University · TRHarran University · TRMersin Üniversitesi · TR

Funding

K VITAMINS--A NEW CLASS OF LIVER CELL GROWTH INHIBITORSR01CA082723 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CARR, BRIAN I · 2000 to 2008
$2.3M
NCI NIH HHS R01 CA082723
6 · The paper itself

Abstract

introductionHepatocellular carcinoma is associated with several chronic inflammatory conditions. It is increasingly understood that the inflammation may be part of the carcinogenic process and prognostically important.

objectiveTo evaluate the serum levels of three inflammation markers in relation to survival in HCC patients.

methodsWe retrospectively examined the serum levels of CRP, albumin and ESR, both singly and in combination, in relation to patient survival.

resultsSurvival worsened with increase in CRP or ESR or decrease in albumin levels. Combinations of CRP plus albumin or CRP plus ESR were associated with an even greater range of survival (3-fold), together with significant differences in maximum tumor diameter (PVT) and percent of patients with portal vein thrombosis (PVT). The triplet of CRP plus albumin plus ESR was associated with a sevenfold difference in survival, comparing low vs high parameter levels. These significant differences were found in patients with small or large tumors.

conclusionsCombinations of CRP with albumin or ESR or all three parameters together significantly related to differences in survival and to differences in MTD and percent PVT, in patients with both small and large size HCCs.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAlbuminsBiomarkersC-Reactive ProteinHumansRetrospective StudiesAlbuminsBiomarkersC-Reactive Protein

Identifiers

PMID32583494
PMCPMC7758189
OpenAlexW3037503885

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.